Cargando…

Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome

RATIONALE: Multiple drugs are known to induce metabolic malfunctions, among them second-generation antipsychotics (SGAs). The pathogenesis of such adverse effects is of multifactorial origin. OBJECTIVES: We investigated whether SGAs drive dysbiosis, assessed whether gut microbiota alterations affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Skonieczna-Żydecka, Karolina, Łoniewski, Igor, Misera, Agata, Stachowska, Ewa, Maciejewska, Dominika, Marlicz, Wojciech, Galling, Britta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598971/
https://www.ncbi.nlm.nih.gov/pubmed/30460516
http://dx.doi.org/10.1007/s00213-018-5102-6
_version_ 1783430864428859392
author Skonieczna-Żydecka, Karolina
Łoniewski, Igor
Misera, Agata
Stachowska, Ewa
Maciejewska, Dominika
Marlicz, Wojciech
Galling, Britta
author_facet Skonieczna-Żydecka, Karolina
Łoniewski, Igor
Misera, Agata
Stachowska, Ewa
Maciejewska, Dominika
Marlicz, Wojciech
Galling, Britta
author_sort Skonieczna-Żydecka, Karolina
collection PubMed
description RATIONALE: Multiple drugs are known to induce metabolic malfunctions, among them second-generation antipsychotics (SGAs). The pathogenesis of such adverse effects is of multifactorial origin. OBJECTIVES: We investigated whether SGAs drive dysbiosis, assessed whether gut microbiota alterations affect body weight and metabolic outcomes, and looked for the possible mechanism of metabolic disturbances secondary to SGA treatment in animal and human studies. METHODS: A systematic literature search (PubMed/Medline/Embase/ClinicalTrials.gov/PsychInfo) was conducted from database inception until 03 July 2018 for studies that reported the microbiome and weight alterations in SGA-treated subjects. RESULTS: Seven articles reporting studies in mice (experiments = 8) and rats (experiments = 3) were included. Olanzapine was used in five and risperidone in six experiments. Only three articles (experiments = 4) in humans fit our criteria of using risperidone and mixed SGAs. The results confirmed microbiome alterations directly (rodent experiments = 5, human experiments = 4) or indirectly (rodent experiments = 4) with predominantly increased Firmicutes abundance relative to Bacteroidetes, as well as weight gain in rodents (experiments = 8) and humans (experiments = 4). Additionally, olanzapine administration was found to induce both metabolic alterations (adiposity, lipogenesis, plasma free fatty acid, and acetate levels increase) (experiments = 3) and inflammation (experiments = 2) in rodents, whereas risperidone suppressed the resting metabolic rate in rodents (experiments = 5) and elevated fasting blood glucose, triglycerides, LDL, hs-CRP, antioxidant superoxide dismutase, and HOMA-IR in humans (experiment = 1). One rodent study suggested a gender-dependent effect of dysbiosis on body weight. CONCLUSIONS: Antipsychotic treatment-related microbiome alterations potentially result in body weight gain and metabolic disturbances. Inflammation and resting metabolic rate suppression seem to play crucial roles in the development of metabolic disorders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00213-018-5102-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6598971
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-65989712019-07-18 Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome Skonieczna-Żydecka, Karolina Łoniewski, Igor Misera, Agata Stachowska, Ewa Maciejewska, Dominika Marlicz, Wojciech Galling, Britta Psychopharmacology (Berl) Review RATIONALE: Multiple drugs are known to induce metabolic malfunctions, among them second-generation antipsychotics (SGAs). The pathogenesis of such adverse effects is of multifactorial origin. OBJECTIVES: We investigated whether SGAs drive dysbiosis, assessed whether gut microbiota alterations affect body weight and metabolic outcomes, and looked for the possible mechanism of metabolic disturbances secondary to SGA treatment in animal and human studies. METHODS: A systematic literature search (PubMed/Medline/Embase/ClinicalTrials.gov/PsychInfo) was conducted from database inception until 03 July 2018 for studies that reported the microbiome and weight alterations in SGA-treated subjects. RESULTS: Seven articles reporting studies in mice (experiments = 8) and rats (experiments = 3) were included. Olanzapine was used in five and risperidone in six experiments. Only three articles (experiments = 4) in humans fit our criteria of using risperidone and mixed SGAs. The results confirmed microbiome alterations directly (rodent experiments = 5, human experiments = 4) or indirectly (rodent experiments = 4) with predominantly increased Firmicutes abundance relative to Bacteroidetes, as well as weight gain in rodents (experiments = 8) and humans (experiments = 4). Additionally, olanzapine administration was found to induce both metabolic alterations (adiposity, lipogenesis, plasma free fatty acid, and acetate levels increase) (experiments = 3) and inflammation (experiments = 2) in rodents, whereas risperidone suppressed the resting metabolic rate in rodents (experiments = 5) and elevated fasting blood glucose, triglycerides, LDL, hs-CRP, antioxidant superoxide dismutase, and HOMA-IR in humans (experiment = 1). One rodent study suggested a gender-dependent effect of dysbiosis on body weight. CONCLUSIONS: Antipsychotic treatment-related microbiome alterations potentially result in body weight gain and metabolic disturbances. Inflammation and resting metabolic rate suppression seem to play crucial roles in the development of metabolic disorders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00213-018-5102-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-11-20 2019 /pmc/articles/PMC6598971/ /pubmed/30460516 http://dx.doi.org/10.1007/s00213-018-5102-6 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Skonieczna-Żydecka, Karolina
Łoniewski, Igor
Misera, Agata
Stachowska, Ewa
Maciejewska, Dominika
Marlicz, Wojciech
Galling, Britta
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
title Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
title_full Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
title_fullStr Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
title_full_unstemmed Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
title_short Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
title_sort second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598971/
https://www.ncbi.nlm.nih.gov/pubmed/30460516
http://dx.doi.org/10.1007/s00213-018-5102-6
work_keys_str_mv AT skoniecznazydeckakarolina secondgenerationantipsychoticsandmetabolismalterationsasystematicreviewoftheroleofthegutmicrobiome
AT łoniewskiigor secondgenerationantipsychoticsandmetabolismalterationsasystematicreviewoftheroleofthegutmicrobiome
AT miseraagata secondgenerationantipsychoticsandmetabolismalterationsasystematicreviewoftheroleofthegutmicrobiome
AT stachowskaewa secondgenerationantipsychoticsandmetabolismalterationsasystematicreviewoftheroleofthegutmicrobiome
AT maciejewskadominika secondgenerationantipsychoticsandmetabolismalterationsasystematicreviewoftheroleofthegutmicrobiome
AT marliczwojciech secondgenerationantipsychoticsandmetabolismalterationsasystematicreviewoftheroleofthegutmicrobiome
AT gallingbritta secondgenerationantipsychoticsandmetabolismalterationsasystematicreviewoftheroleofthegutmicrobiome